Newsroom

Lymphomas from A to Z

Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomason March 10-12, 2017 in Barcelona, Spain. The program, chaired by Professors MJ Kersten and M Dreyling, covered a wide range of different lymphoma subtypes.

The meeting was a unique opportunity to learn about the recent advances in the field and connect with fellow hematologists from around the world. The disease-focused lectures by international experts were an excellent learning opportunity and allowed for attendees to catch up on recent advances in the understanding of lymphoma biology, updates on diagnostics, current management strategies, as well as challenges, and ongoing research.

All 88 participants were content with how the meeting was set-up and would highly recommend it to their colleagues. It received an 8.8 rating out of 10.

Annoir Shayya, a delegate and case pitch presenter from Lebanon described his experience as ‘unforgettable’. “Being part of the EHA meeting in Barcelona was by far the most exciting experience I’ve ever had to go through. As a trainee, you don’t get such opportunities often, and basically this is the main reason why despite the fact that a couple of weeks have passed, I still find it difficult to believe that I was there. From the general vibe, informative and complex presentations, presenting my pitch presentation, to networking with top notch physicians from around the globe this experience was certainly one that would be simply unforgettable,” Shayya said.

Moritz Binder, a delegate and interactive case presenter from the USA considered it a unique opportunity, because the meeting and the case presentations specifically “allowed the discussion of interesting and challenging patients with experts from around the world”. “There was ample opportunity to meet with hematologists in all career stages and the meeting size certainly facilitated interesting conversations,” Binder added.

The meeting was organized with the main support of EHA and unrestricted educational grants provided by Janssen, Celgene, Takeda/Millenium Pharmaceuticals, Pfizer, Bayer, Kite Pharma.

EHA would like to thank the chairs, the scientific program committee, the faculty and the case presenters, and sponsors for their invaluable contribution to this excellent meeting.